

Haematologica
HAEMATOL/2018/191841
Version 3

Gemtuzumab Ozogamicin in children with relapsed or refractory acute myeloid leukemia: a report of Berlin-Frankfurt-Münster study group

Naghmeh Niktoreh, Beate Lerijs, Martin Zimmermann, Bernd Gruhn, Gabriele Escherich, Jean-Pierre Bourquin, Michael Dworzak, Lucie Sramkova, Claudia Rossig, Ursula Creutzig, Dirk Reinhardt, and Mareike Rasche

Disclosures: J.-P.B has consulting or advisory roles for Amgen. C.R. has consulting or advisory roles for Amgen, Celgene, Roche (Genetech), EUSA Pharma, and Pfizer's Hematology Academy. D.R. has consulting or advisory roles for Roche, Celgene, Hexal, Pfizer, Novartis, Boehringer and receives research funding from Celgene. D.R. received travel, accommodation or other expenses from Jazz Pharmaceuticals and Grifols. N.N. received travel accommodation or other expenses from Jazz Pharmaceuticals. Other authors have nothing to declare.

Contributions: N.N., B.L, and M.R. collected and assembled data; M.Z., N.N., M.R., and D.R., analyzed and interpreted data; N.N, B.L. and M.R. wrote the manuscript; and all authors gave final approval of manuscript.